Overview

Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The objective of the trial is to study the safety and effectiveness of ABT-874 administered weekly or every other week in patients with relapsing remitting and secondary progressive multiple sclerosis as compared to placebo. Effectiveness will be measured based on MRI scans done periodically throughout the study.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins